Huahui Health, BeOne Strike $2B HH160 Oncology Deal
BEIJING, CHINA, April 27, 2026 Huahui Health has announced a global exclusive option, license, and collaboration agreement with BeOne...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BEIJING, CHINA, April 27, 2026 Huahui Health has announced a global exclusive option, license, and collaboration agreement with BeOne...
FREDERICK, MARYLAND, April 30, 2026 Theradaptive has received U.S. Food and Drug Administration (FDA) authorization to advance its OASIS...
